Semaglutide is a synthetic version of glucagon-like peptide-1 (GLP-1) and thus mimics the action of this human incretin. Unlike other GLP-1 agonists, semaglutide resists degradation linked to the dipeptidyl peptidase-IV enzyme. Thanks to a mechanism that stimulates insulin and reduces glucagon secretions in a glucose-dependent manner, semaglutide has been shown to reduce fasting and postprandial blood glucose levels.
